US Patent 5,424,286: Claim Scope, Exendin Coverage, Expiration, and Patent Landscape

US Patent 5,424,286 is the foundational U.S. patent covering exendin peptides derived from Heloderma suspectum venom, including exendin-3, exendin-4, truncated exendin analogs, and the insulinotropic antagonist exendin(9-39). The patent issued June 13, 1995, and its original 17-year term expired June 13, 2012. It therefore presents no current U.S. blocking patent risk for exenatide, Byetta, Bydureon, or later GLP-1 receptor agonists.

The claims are narrow sequence claims. They do not broadly cover every GLP-1 receptor agonist, every exendin analog, or every formulation containing exenatide. Later patents, not US 5,424,286, carried most of the commercial protection for exenatide formulations, sustained-release systems, manufacturing processes, and product-specific uses.

What does US Patent 5,424,286 cover?

US 5,424,286 covers five principal subject areas:

Claim group	Subject matter	Key limitation
Claims 1-2	Short exendin peptides	Exact 31-residue sequences ending in proline or tyrosine
Claims 3-4	Pharmaceutical compositions	Claims 1 or 2 in a suitable carrier with insulinotropic activity
Claims 5-6	Insulin-release methods	Full-length exendin-3 or exendin-4, with an effect greater than GLP-1
Claim 7	Insulin-release inhibition	Exendin(9-39), a truncated exendin antagonist

The patent is best understood as a discovery patent for exendin biology and sequence-defined peptides. It is not a broad platform patent covering all peptides that activate the GLP-1 receptor.

The patent’s central technical disclosure is that exendin peptides stimulate insulin secretion and, in certain disclosed comparisons, produce a greater insulinotropic effect than GLP-1. The claims distinguish the peptides by exact amino acid sequence rather than by a broad functional definition.

What sequences are protected by the patent?

Exendin-3 and exendin-4

Claims 5 and 6 cover the full-length 39-amino-acid sequences corresponding to exendin-3 and exendin-4:

Patent sequence	Common identity	Sequence distinction
SEQ ID NO: 1	Exendin-3	Begins HSDGTFITSDL...
SEQ ID NO: 2	Exendin-4	Begins HGEGTFTSDL...

Exendin-4 is the active peptide underlying exenatide, the active ingredient in Byetta and Bydureon. The sequence in claim 6 is:

HGEGTFTS DLSKQMEEEAVR LFIEWLKNGG PSSGAPPPS

Exendin-3 differs principally at the N-terminal region:

HSDGTFITSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS

The N-terminal differences are material. A peptide matching exendin-4 but not exendin-3 would generally be assessed against claim 6, not claim 5.

Truncated exendin peptides

Claims 1 and 2 cover 31-residue truncations:

Claim 1: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG P
Claim 2: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG Y

These are not the full exendin-4 sequence. The claims require exact sequence identity, including the terminal residue. A peptide with a different terminal amino acid, an internal substitution, or a materially different truncation would not literally meet the sequence limitation.

Claim 7 covers exendin(9-39):

DLSKQMEEEAVR LFIEWLKNGG PSSGAPPPS

This sequence omits the N-terminal eight residues present in exendin-4. Claim 7 is a functional method claim directed to inhibiting insulin release, consistent with the use of exendin(9-39) as a GLP-1 receptor antagonist in research and pharmacology.

How broad are the composition claims?

Claims 3 and 4 cover pharmaceutical compositions containing the respective 31-residue peptides of claims 1 and 2.

Each composition claim requires:

The exact claimed peptide sequence.
A substantially pure peptide.
A synthetic or naturally purified source.
An effective insulinotropic amount.
A suitable carrier.
A composition capable of stimulating insulin secretion in vivo.

The claims do not specify a particular dosage form, excipient, route of administration, concentration, container, or release profile. The term "suitable carrier" gives the composition claims some formulation breadth, but the claims remain limited by the specific 31-residue peptides.

The claims do not expressly cover a composition containing full-length exendin-4 unless the accused composition also contains one of the exact 31-residue peptides in claims 1 or 2. Exenatide by itself is the full-length exendin-4 sequence and is more directly implicated by claim 6 than by claims 3 or 4.

Does the patent cover amidated exendin-4?

The listed claims recite amino acid sequences but do not separately state a C-terminal amide, salt form, solvent, counterion, or other chemical modification. Exenatide is commonly described as synthetic exendin-4 with a C-terminal amide. Whether a particular amidated or otherwise modified peptide falls within a sequence claim depends on claim construction, the patent specification, prosecution history, and the chemical identity treated as the claimed polypeptide.

The practical point is that the patent’s commercial significance did not depend on resolving this issue today. The patent expired in 2012.

What do claims 5 and 6 require?

Claims 5 and 6 are method-of-treatment claims. They require administering the exact full-length peptide to a mammal and achieving an insulinotropic effect greater than that attainable by GLP-1.

Claim	Peptide	Activity requirement
5	Exendin-3	Insulin release greater than GLP-1
6	Exendin-4	Insulin release greater than GLP-1

The comparative limitation is significant. A claimant would need to establish that the administered peptide produces an insulinotropic effect greater than GLP-1 under the relevant conditions. The phrase does not simply require insulin release. It adds a comparative efficacy element.

The claims also require an "effective insulinotropic amount." That limitation ordinarily raises questions about dose, route, patient or animal model, assay conditions, and whether the administered amount actually produces the claimed biological effect.

The method claims are narrower than a claim covering administration of exendin-4 for any therapeutic purpose. They specifically target insulin release and include the comparison to GLP-1.

What does claim 7 cover?

Claim 7 covers a method of inhibiting insulin release by administering exendin(9-39):

DLSKQMEEEAVR LFIEWLKNGG PSSGAPPPS

This claim differs pharmacologically from claims 5 and 6. Claims 5 and 6 cover insulinotropic stimulation. Claim 7 covers inhibition of insulin release.

The claim requires:

The exact exendin(9-39) sequence.
A substantially pure peptide.
An effective amount.
Administration to a mammal.
Inhibition of insulin release.

Claim 7 does not cover every GLP-1 receptor antagonist. It is limited to the stated exendin(9-39) sequence.

When did US Patent 5,424,286 expire?

US 5,424,286 issued June 13, 1995. Because the application predates the transition to the modern 20-year-from-earliest-effective-filing-date patent term, the patent was generally subject to the former 17-year term measured from grant. The listed expiration date is June 13, 2012.[1]

Event	Date
Patent issued	June 13, 1995
Original term basis	17 years from grant
Expiration	June 13, 2012
Current status	Expired

There is no current enforceable exclusivity based on US 5,424,286. Patent-term restoration associated with a later approved product cannot revive an already expired foundational patent beyond the statutory limits applicable to that patent and product.

Who owned and commercialized the technology?

The patent was associated with John Eng and the University of Texas system, reflecting the discovery of exendin peptides from Gila monster venom.[1] Commercial development of exendin-4 proceeded through Amylin Pharmaceuticals, which developed exenatide as Byetta and later as the extended-release product Bydureon.

The commercial chain involved several layers:

Layer	Representative party or product
Discovery	University of Texas-associated research and John Eng
Commercial developer	Amylin Pharmaceuticals
Immediate-release product	Byetta, exenatide injection
Extended-release product	Bydureon, exenatide extended-release
Later corporate rights	Transferred through subsequent transactions involving Amylin and its commercial partners

The original patent supplied an early intellectual-property basis for the peptide itself. Commercial value later shifted to patents covering formulation, delivery, manufacturing, dosing, and product-specific regulatory approvals.

What is the Orange Book status of US 5,424,286?

US 5,424,286 is not a current Orange Book barrier to generic exenatide entry. The patent expired before the present generic competition period and cannot support a current Paragraph IV assertion.

FDA-approved exenatide products include:

Product	Active ingredient	Dosage form	FDA role
Byetta	Exenatide	Twice-daily injection	Immediate-release exenatide
Bydureon	Exenatide extended-release	Once-weekly injection	Microsphere extended-release formulation

The Orange Book patent landscape for these products has historically centered on later patents, particularly those directed to extended-release microspheres, formulation components, manufacturing methods, and dosage regimens. Those patents are legally distinct from US 5,424,286.[2][3]

FDA approval of a generic or follow-on product depends on the applicable reference product exclusivity, listed patents, ANDA certification, product sameness, and formulation or device differences. Expiration of US 5,424,286 does not by itself establish immediate market access where later listed patents remain relevant.

Are there Paragraph IV challenges to US 5,424,286?

No current Paragraph IV risk attaches to US 5,424,286 because the patent is expired. Paragraph IV certification is directed to listed patents that remain unexpired and capable of affecting approval or commercial launch.

Historical ANDA activity involving exenatide would have focused on later product patents rather than on the already expired foundational sequence patent. A generic applicant challenging Byetta or Bydureon would typically evaluate:

Listed drug substance patents.
Extended-release formulation patents.
Microsphere or depot manufacturing patents.
Injection-device patents.
Method-of-use patents.
Regulatory exclusivity.
Product-specific pediatric or clinical-study exclusivity.

An expired patent can remain relevant as prior art, prosecution history, or evidence of public disclosure. It cannot independently block launch.

What later patents protected exenatide products?

The later exenatide estate generally falls into five categories.

Drug substance and analog patents

These patents cover exendin-4 derivatives, substitutions, terminal modifications, salts, and related GLP-1 receptor agonists. Their scope depends on the specific sequence and chemical modifications.

Extended-release formulation patents

Bydureon used a long-acting delivery system based on exenatide incorporated into biodegradable microspheres. Patents in this area can cover:

Polymer composition.
Particle size.
Encapsulation method.
Drug loading.
Release kinetics.
Reconstitution and injection requirements.
Manufacturing conditions.

These patents create a more substantial technical barrier than the expired sequence patent because a competing product may need to design around both the formulation claims and the manufacturing claims.

Method-of-use patents

Later patents may cover dosing frequency, titration, treatment populations, glycemic control, or use in combination with other diabetes therapies. Method-of-use patents can remain relevant even when the active peptide itself is no longer patent-protected.

Manufacturing patents

Peptide synthesis, purification, particle formation, sterilization, suspension stability, and scale-up can be protected separately from the drug substance.

Device and presentation patents

Prefilled pens, injection systems, mixing mechanisms, dose delivery, and kit configurations may carry additional patent or design protection.

How strong is the patent estate for US 5,424,286?

The patent estate is historically important but currently weak as an enforcement asset.

Factor	Assessment
Sequence specificity	High
Coverage of full-length exendin-4	Direct through claim 6
Coverage of exendin-3	Direct through claim 5
Coverage of modified GLP-1 agonists	Limited
Coverage of generic formulations	Limited
Coverage of sustained-release systems	None apparent from the listed claims
Current enforceability	None after expiration
Prior-art significance	High
Current commercial blocking value	None

The patent’s strongest historical feature was its direct coverage of exendin-4 by exact sequence. Its principal weakness was the absence of broad claims covering formulations, delivery technologies, analogs, or manufacturing platforms.

How does this patent compare with later GLP-1 patent estates?

Patent estate type	Typical protected subject matter	Current strategic value
US 5,424,286	Native exendin sequences and basic biological uses	Expired; prior-art value only
Exenatide formulation patents	Microspheres, depot systems, release profiles	Historically important for Bydureon
Liraglutide patents	Acylated GLP-1 analog and formulations	Product-specific
Semaglutide patents	Modified GLP-1 sequence, formulations, dosing	Major later-generation estate
Tirzepatide patents	Dual GIP/GLP-1 agonist sequence, formulations, uses	Separate and later estate

Exenatide is a peptide drug, so biosimilar analysis is not the same as antibody biosimilar analysis. The relevant regulatory pathway is generally an abbreviated application or follow-on peptide strategy, not a conventional 351(k) biosimilar pathway used for biological products such as monoclonal antibodies. FDA’s treatment of peptides depends on the product’s statutory classification, reference product, formulation, and route of approval.[2]

What generic entry risks exist for exenatide?

The expired foundational patent creates no standalone entry risk. The principal risks historically arose from the commercial product patents and technical requirements for reproducing the dosage form.

Immediate-release exenatide

The principal barriers are lower once the active sequence patent and core regulatory exclusivities expire. A competitor must still establish pharmaceutical equivalence, device compatibility, stability, and manufacturing consistency.

Extended-release exenatide

The risk profile is more complex. A competing product may need to avoid claims covering the microsphere formulation, polymer system, particle attributes, release profile, reconstitution process, or administration device.

A generic launch could follow several paths:

A formulation that is substantially equivalent and challenges listed patents.
A noninfringing extended-release formulation with different polymer or particle characteristics.
An immediate-release product that does not compete directly with the weekly formulation.
A new drug application for a differentiated long-acting exenatide product.

What geographic coverage remains?

US 5,424,286 has no remaining U.S. patent term. Foreign counterparts would have been governed by national patent terms and filing dates. Because the U.S. patent issued in 1995, corresponding foreign rights would generally have expired no later than the applicable 20-year term measured from the earliest effective filing date, subject to country-specific patent-term adjustments and prosecution events.

The commercial risk after expiration is therefore jurisdiction-specific only for later patents. Companies assessing exenatide entry must separate:

U.S. expired sequence rights.
Foreign expired or lapsed sequence rights.
Later U.S. formulation rights.
Later foreign formulation and manufacturing rights.
Regulatory exclusivity in each market.
Local patent-term extensions or supplementary protection certificates.

Key Takeaways

US 5,424,286 is the foundational exendin patent.
Claims 5 and 6 directly recite exendin-3 and exendin-4.
Claim 7 covers exendin(9-39) as an insulin-release inhibitor.
Claims 3 and 4 cover compositions containing specific 31-residue truncated peptides.
The patent expired June 13, 2012.
It is not a current U.S. Orange Book or Paragraph IV barrier.
Later patents, rather than US 5,424,286, protected Byetta and Bydureon formulation and delivery technologies.
The patent has continuing prior-art and historical importance but no current blocking value.
Exenatide competition is primarily a formulation, manufacturing, device, regulatory, and product-equivalence issue.
Exenatide should be analyzed separately from antibody biosimilars and later GLP-1/GIP agonist patent estates.

FAQs

Does US 5,424,286 cover Byetta?

It covers the exendin-4 sequence underlying Byetta through claim 6, but the patent expired in 2012. It does not currently block Byetta-related generic development.

Does the patent cover semaglutide or liraglutide?

No. Semaglutide and liraglutide are structurally distinct GLP-1 receptor agonists protected by separate patent families.

Is exendin(9-39) a GLP-1 drug?

No. Exendin(9-39) is an exendin-derived GLP-1 receptor antagonist used primarily as a pharmacological research tool and covered by the expired claim 7 method.

Can a company patent a new exenatide formulation after the sequence patent expires?

Yes. A later patent may protect a novel formulation, delivery system, manufacturing process, device, or therapeutic regimen even after the original peptide sequence patent expires.

Does expiration of the peptide patent guarantee FDA approval of a generic exenatide product?

No. Approval depends on the applicable FDA pathway, reference product requirements, formulation and device equivalence, listed patents, exclusivity, manufacturing controls, and product-specific regulatory obligations.

References

United States Patent and Trademark Office. (1995). US Patent No. 5,424,286: Exendins: Insulinotropic peptides from Heloderma suspectum venom. U.S. Department of Commerce. https://patents.google.com/patent/US5424286
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2023). Byetta (exenatide) injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry, 267(11), 7402-7405.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Patent and exclusivity information. https://www.fda.gov/drugs/development-resources/drug-approvals-and-databases

Details for Patent: 5,424,286

Summary for Patent: 5,424,286